Click here for file(186K, pdf) Acknowledgements This survey could not have been done without the

financial support of the Institut National d’Etudes Démographiques and the Health Ministry’s Direction Générale de la Santé (represented by A. Fontaine and E. Gaillard). We would like to thank: – The survey’s steering committee for their support and constructive discussions throughout the design and first analysis of the survey (Piernick Cressard and Francois Stefani of the Conseil National de l’Ordre des Médecins – National medical council -, Eric Jougla, Albertine Aouba, Grégoire Rey of CepiDc at Inhibitors,research,lifescience,medical Institut national de la Santé et de la Recherche médicale – French national Institute of health and medical research-); – Chantal Cases, Director of Ined for her constant support throughout the survey and her advice Inhibitors,research,lifescience,medical on data analysis; – Our “trusted third party” partners

Jeanne Fresson of the Department of Medical Information at the Maternité Universitaire de Nancy and Epiconcept for the Internet response channel; – INED’s surveys department, which was the pillar for data collection, and Amandine Stephan for her see more contribution in coordinating the survey; – INED’s administration; Inhibitors,research,lifescience,medical IT department and statistical methods department for their involvement in different aspects of this project; – Johan Bilsen and Joachim Cohen from the End-of-life Care research group at the Vrije universiteit Brussel for

their advice on Inhibitors,research,lifescience,medical the design of the survey; – Françoise Riou for her comments on the manuscript – All those who have been involved in the different steps of this survey (questionnaire testing, pilot survey, data capture…) And of course, all our thanks and gratitude to all the physicians who gave their time to take part in the survey.
There is a lack of evidence developed or validated within a stroke context to help clinicians meet the palliative care needs of patients and families. Inhibitors,research,lifescience,medical Synthesising earlier research which prospectively identified stroke patients’ palliative care problems and needs [1], experiences and preferences [2] and staff perspectives, this paper provides the first theoretical explanation of how palliative care and acute stroke 3-mercaptopyruvate sulfurtransferase care can be integrated around the needs and preferences of patients and families. Despite advances in the early identification and clinical management of patients with stroke, a significant proportion of patients die in the acute phase. Most recent estimates suggest that the 30-day mortality rate is 17% [3], although there is variation in mortality rates across stroke sub-type [4]. In the United Kingdom (UK), successive editions of national guidelines have recognised the importance of providing access to palliative care for patients at the end of life.